- Home
- ASMB vs ICG Comparison
ASMB vs ICG Comparison
Compare ASMB & ICG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- ICG
- Stock Information
- Founded
- ASMB 2005
- ICG 2017
- Country
- ASMB United States
- ICG China
- Employees
- ASMB N/A
- ICG N/A
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- ICG Semiconductors
- Sector
- ASMB Health Care
- ICG Technology
- Exchange
- ASMB Nasdaq
- ICG Nasdaq
- Market Cap
- ASMB 130.2M
- ICG 105.7M
- IPO Year
- ASMB 2010
- ICG 2023
- Fundamental
- Price
- ASMB $17.31
- ICG $1.69
- Analyst Decision
- ASMB Strong Buy
- ICG Strong Buy
- Analyst Count
- ASMB 3
- ICG 2
- Target Price
- ASMB $33.00
- ICG $9.25
- AVG Volume (30 Days)
- ASMB 32.4K
- ICG 147.5K
- Earning Date
- ASMB 08-07-2025
- ICG 08-14-2025
- Dividend Yield
- ASMB N/A
- ICG N/A
- EPS Growth
- ASMB N/A
- ICG N/A
- EPS
- ASMB N/A
- ICG 0.07
- Revenue
- ASMB $32,154,000.00
- ICG $53,729,346.00
- Revenue This Year
- ASMB $0.04
- ICG N/A
- Revenue Next Year
- ASMB N/A
- ICG $141.94
- P/E Ratio
- ASMB N/A
- ICG $23.45
- Revenue Growth
- ASMB 148.33
- ICG 384.54
- 52 Week Low
- ASMB $7.75
- ICG $1.19
- 52 Week High
- ASMB $19.93
- ICG $12.04
- Technical
- Relative Strength Index (RSI)
- ASMB 68.78
- ICG 42.79
- Support Level
- ASMB $16.50
- ICG $1.19
- Resistance Level
- ASMB $17.94
- ICG $2.03
- Average True Range (ATR)
- ASMB 0.82
- ICG 0.25
- MACD
- ASMB -0.07
- ICG -0.03
- Stochastic Oscillator
- ASMB 73.75
- ICG 49.50
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.